NEW YORK (GenomeWeb News) – HyperGenomics has signed a contract with an undisclosed partner that is expected to provide the firm with its first revenues, its parent firm VolitionRx said today.
The deal calls for Singapore-based VolitionRx to develop epigenetic profiling signatures from blood and makes HyperGenomics eligible for payments of up to a total of US$55,000 if milestones are met during the next eight months.
HyperGenomics is partnering with Biomedicum Genomics in Finland for the sequencing and bioinformatics part of the workflow.
HyperGenomics' technology is based on cutting up a genome at certain spots and then sequencing it. The company's tests are planned for use as a second line upon the diagnosis of cancer, or other disease, in order to determine the specific subtype and decide the most appropriate therapy, it said.